HC Wainwright Reiterates “Neutral” Rating for 60 Degrees Pharmaceuticals (NASDAQ:SXTP)

60 Degrees Pharmaceuticals (NASDAQ:SXTP)‘s stock had its “neutral” rating reaffirmed by research analysts at HC Wainwright in a report issued on Friday,Benzinga reports.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of 60 Degrees Pharmaceuticals in a research note on Saturday, March 22nd.

60 Degrees Pharmaceuticals Stock Up 2.2 %

Shares of SXTP opened at $1.86 on Friday. 60 Degrees Pharmaceuticals has a twelve month low of $1.41 and a twelve month high of $35.99. The stock has a market capitalization of $2.74 million, a P/E ratio of -0.18 and a beta of 4.52. The company has a 50 day moving average of $2.61 and a 200-day moving average of $4.62.

60 Degrees Pharmaceuticals Company Profile

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.